| 摘要: |
| 肝癌是临床常见的恶性肿瘤之一,在全球最常见恶性肿瘤中居第六位,在肿瘤相关致死率中占第三位。由于多数肝癌患者确诊时已是晚期,且对于晚期原发性肝癌缺乏有效的治疗措施,肝癌的治疗仍然是临床一大难题。临床上放射性治疗和肝移植手术等只对早期肝癌有效,对于晚期原发性肝癌的治疗多采用全身系统性治疗,主要包括分子靶向药物治疗,化疗等,其中索拉非尼是晚期肝癌药物治疗的金标准。本文对晚期原发性肝癌药物治疗最新进展作一综述 |
| 关键词: 晚期原发性肝癌 分子靶向治疗化疗 药物治疗 |
| DOI:10.13506/j.cnki.jpr.2018.02.012 |
| 基金项目: |
|
|
|
| Progress in pharmacotherapy for the advanced hepatocellular carcinoma |
| CUI Tingting,YANG Yong |
| (Institute of Pharmaceutical Science,China Pharmaceutical University,Nanjing 211198,China) |
| Abstract: |
| Hepatocellular carcinoma (HCC) is the sixth common primary tumor.and the third cause of cancer-related death worldwide.Despite the spread of HCC,its treatment is still a hard challenge, due to high rate of late diagnosis and to lack of therapeutic options for advanced disease. In fact radical surgery and liver transplantation, the most radical therapeutic approaches, are indicated only in case of early diagnosis.Systemic therapy is particularly important for patients with advanced HCC,including targeted agent therapy and chemotherapy,with sorafenib as the only standard treatment available.In this review,we discussed the current situation and progress of systemic therapies for the advanced HCC. |
| Key words: Hepatocellular carcinoma Targeted agent therapy chemotherapy Pharmacotherapy |